Compare Inovio Pharmaceuticals Inc (INO) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Okta, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Okta, Inc. trades at $143.27 (market cap $25.79B). The key difference: Okta, Inc. is far larger — about 288.9× Inovio Pharmaceuticals Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | OKTA | |
|---|---|---|
Market Cap | $89.27M | $25.79B |
Sector | Health | Technology |
52-Week High | $2.87 | $154.62 |
52-Week Low | $1.05 | $62.93 |
Enterprise Value | $60.28M | $23.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
OKTA trades at $150.64, up 0.86% today, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.96. Revenue growth accelerated to $2.61B in 2025, achieving positive net income of $28M after years of losses, while operating cash flow surged to $750M. Recent news highlights AI-driven cybersecurity demand boosting Okta's identity protection solutions.
Outlook is positive given earnings momentum and sector tailwinds, but high valuation multiples (P/E 108.22) pose risks if growth slows. Analyst consensus is strongly bullish with a $125.78 price target, though competitive pressures and macroeconomic volatility remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
